Literature DB >> 33572595

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine.

Stanislaw Supplitt1, Pawel Karpinski1,2, Maria Sasiadek1, Izabela Laczmanska1.   

Abstract

Over the last decades, transcriptome profiling emerged as one of the most powerful approaches in oncology, providing prognostic and predictive utility for cancer management. The development of novel technologies, such as revolutionary next-generation sequencing, enables the identification of cancer biomarkers, gene signatures, and their aberrant expression affecting oncogenesis, as well as the discovery of molecular targets for anticancer therapies. Transcriptomics contribute to a change in the holistic understanding of cancer, from histopathological and organic to molecular classifications, opening a more personalized perspective for tumor diagnostics and therapy. The further advancement on transcriptome profiling may allow standardization and cost reduction of its analysis, which will be the next step for transcriptomics to become a canon of contemporary cancer medicine.

Entities:  

Keywords:  RNA; cancer; oncogenesis; personalized medicine; transcriptomics

Year:  2021        PMID: 33572595      PMCID: PMC7866970          DOI: 10.3390/ijms22031422

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  14 in total

1.  Prediction of EVT6-NTRK3-Dependent Papillary Thyroid Cancer Using Minor Expression Profile.

Authors:  A A Kechin; A A Ivanov; A E Kel; A S Kalmykov; I P Oskorbin; U A Boyarskikh; E A Kharpov; S Yu Bakharev; N A Oskina; O V Samuilenkova; I V Vikhlyanov; N E Kushlinskii; M L Filipenko
Journal:  Bull Exp Biol Med       Date:  2022-06-23       Impact factor: 0.804

Review 2.  Multiomics Analysis-Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome.

Authors:  Shikha Rani; Piyush Chandna
Journal:  Reprod Sci       Date:  2022-01-27       Impact factor: 3.060

3.  Investigating the impact of RNA integrity variation on the transcriptome of human leukemic cells.

Authors:  Suliman A Alsagaby
Journal:  3 Biotech       Date:  2022-07-07       Impact factor: 2.893

4.  Development and Validation of an 8-Gene Signature to Improve Survival Prediction of Colorectal Cancer.

Authors:  Leqi Zhou; Yue Yu; Rongbo Wen; Kuo Zheng; Siyuan Jiang; Xiaoming Zhu; Jinke Sui; Haifeng Gong; Zheng Lou; Liqiang Hao; Guanyu Yu; Wei Zhang
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

5.  Overexpression of DDIT4 and TPTEP1 are associated with metastasis and advanced stages in colorectal cancer patients: a study utilizing bioinformatics prediction and experimental validation.

Authors:  Fahimeh Fattahi; Jafar Kiani; Mahdi Alemrajabi; Ahmadreza Soroush; Marzieh Naseri; Mohammad Najafi; Zahra Madjd
Journal:  Cancer Cell Int       Date:  2021-06-09       Impact factor: 5.722

6.  Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma.

Authors:  Pankaj Ahluwalia; Meenakshi Ahluwalia; Ashis K Mondal; Nikhil Sahajpal; Vamsi Kota; Mumtaz V Rojiani; Amyn M Rojiani; Ravindra Kolhe
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

Review 7.  Recent Major Transcriptomics and Epitranscriptomics Contributions toward Personalized and Precision Medicine.

Authors:  Ghada Mubarak; Farah R Zahir
Journal:  J Pers Med       Date:  2022-02-01

Review 8.  Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy.

Authors:  Fanghua Chen; Junming Wang; Yingcheng Wu; Qiang Gao; Shu Zhang
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

9.  Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma.

Authors:  Zengyu Feng; Hao Qian; Kexian Li; Jianyao Lou; Yulian Wu; Chenghong Peng
Journal:  Front Mol Biosci       Date:  2021-05-21

Review 10.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.